Nasopharyngeal carcinoma, susceptibility to, 1
MONDO:0011775Any nasopharyngeal carcinoma in which the cause of the disease is a mutation in the TP53 gene.
Also known as: TP53 nasopharyngeal carcinoma, nasopharyngeal carcinoma 1, nasopharyngeal carcinoma caused by mutation in TP53, nasopharyngeal carcinoma, somatic, nasopharyngeal carcinoma, susceptibility to, 1, NPC, Npca, nasopharyngeal cancer
53 clinical trials for this condition and its sub-types, 21 tagged with Nasopharyngeal carcinoma, susceptibility to, 1 itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
New hope for tough cancers: experimental drug IMGS-001 enters human trials
Disease control Recruiting nowThis early-stage study tests an experimental drug called IMGS-001 in about 105 people with advanced solid tumors that have come back or not improved after standard treatments. The goal is to find a safe dose and see if the drug can shrink tumors. The study has two parts: first, t…
Phase 1 • Sponsor: ImmunoGenesis • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Could less radiation be just as good for some throat cancers?
Disease control Recruiting nowThis study looks at whether people with a type of throat cancer linked to the Epstein-Barr virus can safely receive lower doses of radiation after initial chemotherapy. The goal is to see if reducing radiation can still control the cancer while causing fewer long-term side effect…
Sponsor: University of California, San Francisco • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug BL-B01D1 targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis early-phase study tests a new drug called BL-B01D1 in people with advanced lung cancer or other solid tumors that have spread or cannot be removed. The main goals are to check the drug's safety, find the best dose, and see if it helps shrink tumors. About 470 adults will tak…
Phase 1 • Sponsor: SystImmune Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New cocktail of drugs shows promise for nasopharyngeal cancer
Disease control Recruiting nowThis phase 2 trial tests whether adding two immunotherapy drugs (pembrolizumab and bevacizumab) to standard chemotherapy (gemcitabine and cisplatin) works better for advanced nasopharyngeal cancer. About 50 participants will be randomly assigned to receive either the standard che…
Phase 2 • Sponsor: National University Hospital, Singapore • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
New imaging agent could spot multiple cancers with one scan
Diagnosis Recruiting nowThis study is testing a new type of PET scan that uses special radioactive tracers to find and map solid tumors in the body. The tracers target a protein called Trop2, which is often found on cancer cells. Researchers will enroll 400 people with various cancers (including bladder…
Phase 2/3 • Sponsor: RenJi Hospital • Aim: Diagnosis
Last updated Jun 27, 2026 13:00 UTC
-
Early jaw exercises may prevent lockjaw in cancer patients
Symptom relief Recruiting nowThis study tests whether closely watching jaw movement and starting physical therapy early can prevent or reduce trismus (jaw tightness) in people receiving radiation for head and neck cancer. Thirty adults will be checked weekly during treatment and given jaw exercises if their …
Sponsor: University of Alberta • Aim: Symptom relief
Last updated Aug 14, 2026 00:00 UTC
-
Massive cancer database aims to unlock secrets of the disease
Knowledge-focused Recruiting nowThis study is building a huge registry of information and biological samples from adults with or at risk for many types of cancer, as well as healthy volunteers. Researchers will use this resource to study what causes cancer and how to better prevent, detect, and treat it. The re…
Sponsor: University of Nebraska • Aim: Knowledge-focused
Last updated Jul 01, 2026 00:00 UTC